Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.

Abstract

Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexpressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5 degrees C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.

• Authors: Akira Ito, Yuko Kuga, Hiroyuki Honda, Hiroyuki Kikkawa, Atsushi Horiuchi, Yuji Watanabe, Takeshi Kobayashi
• Journal: Cancer letters (Cancer Lett) Vol. 212 Issue 2 Pg. 167-75 (Aug 30 2004) ISSN: 0304-3835 [Print] Ireland
• PMID: 15279897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Liposomes
• Oxides
• Iron
• Receptor, ErbB-2
• Trastuzumab
• Ferrosoferric Oxide

Topics

• Antibodies, Monoclonal (pharmacology)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (metabolism, therapy)
• Cell Division
• Cell Line, Tumor
• Cell Survival
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Ferrosoferric Oxide
• Fever
• Humans
• Immunotherapy (methods)
• Iron
• Liposomes (chemistry)
• Magnetics
• Oxides
• Receptor, ErbB-2 (chemistry)
• Temperature
• Time Factors
• Trastuzumab